Fox Chase Cancer Center

Cleveland Clinic's Dr. Matt Kalaycio Appointed Chair of Board of Directors for National Comprehensive Cancer Network

Retrieved on: 
Monday, April 8, 2024
Clinical research, Stanford Cancer Institute, Hematology, Oncology, Associate, Caregiver, Colorectal cancer, Education, Chairperson, Patient, FACP, Research, NCCN, University, Cancer, Glomus tumor, Fox Chase Cancer Center, Leukemia, MBA, FRCP, MPH, Drug development, Health, Management

PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
  • He is Vice-Chair of Cleveland Clinic Cancer Institute and a professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
  • "As I take on the role of Chair of the NCCN Board of Directors, I eagerly anticipate further advancing the organization's mission."
  • "I am very honored to serve as the Vice-Chair of the NCCN Board of Directors," said Dr. Lieu.

2024 Oncology Nurse Advisor Summit Shatters Attendance Records

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Nursing, Education, Health, Continuing, Training, Diagnosis, RN, MHA, Inclusion, NACE, CPPS, Faculty, NSCLC, Real, ONA, American Cancer Society, Knowledge, DNP, Accreditation, Oncology nursing, AANP, Merck, Fox Chase Cancer Center, Bristol Myers Squibb, Oncology Nursing Certification Corporation, MSN, ANCC, Johnson & Johnson, Merck & Co., Summit, National Association, Hematology, Skin cancer, HMN, HME

Over 2,200 attendees enriched their knowledge in disease-specific and supportive care topics during the 9th Annual Oncology Nurse Advisor (ONA) Summit, which occurred from March 21-24, 2024.

Key Points: 
  • Over 2,200 attendees enriched their knowledge in disease-specific and supportive care topics during the 9th Annual Oncology Nurse Advisor (ONA) Summit, which occurred from March 21-24, 2024.
  • New to the 2024 Summit was a one-day pre-conference Hematology Intensive on March 21 titled, What’s Blood Got to Do With It?
  • Also new to the Summit was the Real Solutions Virtual Poster Gallery, which presented real-life, innovative strategies and quality improvement solutions submitted by oncology nurses, which were selected for the Summit through a blind review by ONA Summit course directors.
  • Paula Anastasia, MN, RN, AOCN®, GYN Oncology Clinical Nurse Specialist, UCLA Health Sciences, participated in the Summit as Clinical Advisor, Peer Reviewer and Expert Moderator.

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, March 18, 2024
Research, Technology, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Other Science, Lymphoma, Patient, GBM, Artificial intelligence, Brain, Metadata, Pancreatic cancer, Lung cancer, Mantle cell lymphoma, Clinical trial, Therapy, Harmonic, ATM, USD, PD-1, MCL, DHL, Central nervous system, CNS, DNA, Starlight, Fox Chase Cancer Center, Glioblastoma, Cancer, Safety, Liquid biopsy, Calendar, ADC, TP53, NSCLC, ATRT, AI, AACR, Drug development, Machine learning, FDA, Annual general meeting, Incidence, Triple-negative breast cancer, NHL, Patent, Pharmaceutical industry

“This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for our programs and our AI platform at Lantern Pharma.

Key Points: 
  • “This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for our programs and our AI platform at Lantern Pharma.
  • During the 4th quarter of 2023, Lantern filed 3 new patent applications culminating in 11 new patent applications for the calendar year 2023.
  • The cash burn rate for the 4th quarter and full year of 2023 continues to reflect our capital-efficient, collaborator-centered business model.
  • Full Year Net Loss: Net loss per share was $1.47 per share for the fiscal year 2023 compared to $1.31 per share for the fiscal year 2022.

New National Survey by Desai Sethi Urology Institute Reveals Impact of Technology & Multidisciplinary Collaboration on the Future of Urology

Retrieved on: 
Monday, January 22, 2024
Artificial intelligence, Patient, Research, Report, Health, Global health, Field, University, AI, Medicine, Radiology, UCLA, Biomedical engineering, Cleveland Clinic, Machine learning, Fox Chase Cancer Center, YouGov, Education, General practitioner, Nursing

MIAMI, Jan. 22, 2024 /PRNewswire/ -- The Desai Sethi Institute of Urology (DSUI) at the University of Miami Miller School of Medicine unveiled the findings of its inaugural State of Urology survey and report today, which provides insights into the current landscape of urology and outlines implications for the future direction of the specialty. The report captures the perspectives of urologists and the general public on critical issues and emerging trends in urology.

Key Points: 
  • The report captures the perspectives of urologists and the general public on critical issues and emerging trends in urology.
  • The survey reveals a strong consensus among urologists on the importance of cross-disciplinary collaboration.
  • Nearly half (47%) of urologists identified the development of new technologies as the most impactful trend in the coming years.
  • For more information about the DSUI State of Urology Survey & Report, visit med.miami.edu/plp/dsui .

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

Retrieved on: 
Wednesday, December 20, 2023
Myriad, HRD, Medicine, MYGN, Research, Fox Chase Cancer Center, MSI, Health, IRB, Genetics, Cancer, DNAnexus, TMB, Myriad Genetics, Institutional review board, Genetic testing, Patient, Microsatellite instability, MCRR, Pharmaceutical industry

SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry ™ (MCRR).

Key Points: 
  • SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry ™ (MCRR).
  • The latest enhancements make the MCRR one of the largest pan-cancer registries freely available for research use and supports transparent clinical data sharing to advance the field.
  • Built on DNAnexus, a leading enterprise Precision Health platform, the MCRR provides a secure and easy-to-use interface for scientific data analysis, collaboration, and discovery.
  • Myriad is accepting research concept forms from individuals and institutions seeking to undertake research projects.

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 8, 2023
Data Management, Other Health, Technology, Pharmaceutical, Oncology, General Health, Hospitals, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, NSCLC, GBM, DHL, Mantle cell lymphoma, Artificial intelligence, BBB, Lung, Rituximab, IO, USD, AI, Starlight, Lung cancer, Liver, Permeability, Antibody, Cancer, Machine learning, Pancreatic cancer, Brain, NHL, Safety, Therapy, Liquid biopsy, Patient, D, Central nervous system, DNA, Automation, ATM, Johns Hopkins School of Medicine, PD-1, Spacecraft, Fox Chase Cancer Center, MCL, Society, Education, Incidence, Patent, Bone marrow, Harmonic, CNS, Drug development, PDX, Algorithm, Breast, Glioblastoma, Metadata, Pharmaceutical industry, Medical device, Medical imaging, Nursing, Cryptocurrency, Lantern

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter ended September 30, 2023.
  • Lantern plans to release additional details and data on this set of results with LP-284 in this setting in the coming month.
  • G&A Expenses: General and administrative expenses were approximately $1.3 million for the quarter ended September 30, 2023, compared to approximately $1.4 million for the quarter ended September 30, 2022.
  • Earnings Call and Webinar Details:
    Lantern will host its third quarter 2023 earnings call and webinar today, November 8, 2023, at 4:30 p.m.

ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

Retrieved on: 
Friday, October 27, 2023
Research, ORY, Fruit, DMC, Food, Deficit spending, Risk, Medicine, ECNP, Schizophrenia, Platinum, ICMJE recommendations, SCLC, Charcot–Marie–Tooth disease, Sciatic nerve, Psychotherapy, Paclitaxel, NET, FCCC, MRD, Safety, EVOLUTION, BPD, Kabuki syndrome, Patient, Borderline personality disorder, ALS, Fox Chase Cancer Center, Genomics, Human, Duration, Glomus tumor, Measure (mathematics), Clinical trial, Dor, DSM-IV codes, Animal, European College of Neuropsychopharmacology, LSD1, FMS, CMT, FDA, IND, Innovation, ISIN, CNS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, HOPE, AML, Failure, Medical device, Pharmaceutical industry, Nursing, Cryptocurrency, EU, Science

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.
  • The company has started a structured dialogue with corporate pharma to identify a suitable partner to move forward the asset to Phase III, pending positive results.
  • General and administrative expenses were $0.7 and $2.9 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.3 million for the quarter and nine months ended September 30, 2022.
  • Net losses were $0.8 and $3.4 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.9 million for the quarter and nine months ended September 30, 2022.

Nucleus RadioPharma Secures $56 Million Series A Funding to Expand Production of Radiopharmaceutical Treatments for Cancer Patients

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Eclipse, PDX, Cancer, Mayo Clinic, Nucleus, Hope, Mercy Health, Radiopharmaceutical, University of Missouri, University, GE, Software, Fox Chase Cancer Center, Patient, Pharmaceutical industry, Medical imaging

Radiopharmaceuticals offer a highly targeted approach to a wide variety of cancer types and stages.

Key Points: 
  • Radiopharmaceuticals offer a highly targeted approach to a wide variety of cancer types and stages.
  • Nucleus RadioPharma was founded and built to ensure cancer patients can access potentially lifesaving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these promising new therapies.
  • “Theranostic radiopharmaceuticals are offering promise for millions who currently have limited treatment options,” said Charles S. Conroy, CEO of Nucleus RadioPharma.
  • “We co-founded Nucleus RadioPharma, and are leading their Series A, to propel the radiopharmaceutical industry forward,” said Justin Butler, Partner at Eclipse.

ORYZON to Provide Corporate Progress Updates at Several Events in October

Retrieved on: 
Monday, October 2, 2023
Borderline personality disorder, Genomics, ESMO, The Yale Club of New York City, Jefferies, Kendall Square, Oncology, Fox Chase Cancer Center, CNS, Congress, European College of Neuropsychopharmacology, ORY, FCCC, ISIN, Roth Capital Partners, ECNP, European Society for Medical Oncology, Conference, Pharmaceutical industry, Cryptocurrency

Oryzon will participate in the East-West Biopharma Summit, which will be held on October 2-4 in Kendall Square, Cambridge Mass.

Key Points: 
  • Oryzon will participate in the East-West Biopharma Summit, which will be held on October 2-4 in Kendall Square, Cambridge Mass.
  • (USA), and virtually.
  • The company will provide a corporate update and will also hold one-on-one meetings with US and Chinese pharmaceutical companies and investors.
  • Click on link for more info about the ESMO 2023 congress

CHOP Researchers Develop Universal MHC Molecules that Can be Produced Rapidly at Scale

Retrieved on: 
Tuesday, June 13, 2023
Vaccine, National academy, Fox Chase Cancer Center, Human, University, CHOP, HLA, NMR, Neoplasm, Membrane protein, 3D, Coronary heart disease, susceptibility to, 8, Winters, MHC, Cancer, Philadelphia, MR1, Recycling, Genetic distance, Immunotherapy, Doctor of Philosophy, Dicarboxylic acid, Associate, TCR, Protein, Computation, Engineering, Immune system, DOI, Epitope, Hospital, NIAID, Virus, Library, Peptide, Children's Hospital of Philadelphia, Pharmaceutical industry, Fine chemical, NIDDK, Child, Science

PHILADELPHIA, June 13, 2023 /PRNewswire/ -- Class I major histocompatibility complex (MHC-I) proteins play an essential role in the immune system of all jawed vertebrates. The MHC-I displays peptide fragments of proteins from within the cell on the cell surface, "presenting" them to the immune system, which is constantly scanning the body for foreign or toxic antigens. When foreign peptides are identified, they trigger a cascade that allows cytotoxic T cells to eliminate intruders. This process has been exploited in the development of both vaccines and immunotherapy, wherein researchers identify fragments of peptides unique to viruses or cancer and then screen for T cells that recognize those targets and initiate an immune response.

Key Points: 
  • However, the current process of using MHC-I molecules as probes in vaccine and immunotherapy development is laborious.
  • MHC-I molecules are extremely unstable, and making just one of these molecules can take a week, making it prohibitive to scan large libraries of peptides in an efficient manner.
  • Now, researchers from Children's Hospital of Philadelphia (CHOP) have potentially solved this problem by engineering stable, universal MHC-I molecules that can be produced rapidly at scale, allowing researchers not only to develop vaccines and immunotherapies more quickly but also to identify molecules that can work broadly across the population.
  • "Universal open MHC-I molecules for rapid peptide loading and enhanced complex stability across HLA allotypes," Proceedings of the National Academy of Sciences, online June 13, 2023, DOI: 10.1073/pnas.2304055120.